Abstract We have investigated the breakpoints in a male child with pharmacoresistant epileptic encephalopathy and a de novo balanced translocation t(Y;4)(q11.2;q21). By fluorescence in situ hybridisation, we have identified genomic clones from both chromosome 4 and chromosome Y that span the breakpoints. Precise mapping of the chromosome 4 breakpoint indicated that the c-Jun N-terminal kinase 3 (JNK3) gene is disrupted in the patient. This gene is predominantly expressed in the central nervous system, and it plays an established role in both neuronal differentiation and apoptosis. Expression studies in the patient lymphoblastoid cell line show that the truncated JNK3 protein is expressed, i.e. the disrupted transcript is not immediately subject to nonsense-mediated mRNA decay, as is often the case for truncated mRNAs or those harbouring premature termination codons. Over-expression studies with the mutant protein in various cell lines, including neural cells, indicate that both its solubility and cellular localisation differ from that of the wild-type JNK3. It is plausible, therefore, that the presence of the truncated JNK3 disrupts normal JNK3 signal transduction in neuronal cells. JNK3 is one of the downstream effectors of the GTPase-regulated MAP kinase cascade, several members of which have been implicated in cognitive function. In addition, two known JNK3-interacting proteins, barrestin 2 and JIP3, play established roles in neurite outgrowth and neurological development. These interactions are likely affected by a truncated JNK3 protein, and thereby provide an explanation for the link between alterations in MAP kinase signal transduction and brain disorders.
Introduction
The molecular characterisation of de novo chromosome abnormalities is a useful strategy for elucidating the genetic basis of disease. In particular, balanced translocations, which are not accompanied by loss of genetic material, can serve as links between specific disorders and single genes. Such chromosome rearrangements may be present in healthy individuals (Warburton 1991) if, for example, no gene or regulatory region is directly affected, or due to the fact that the presence of a single intact copy on the homologous chromosome may be sufficient for normal function. However, the frequency of balanced translocations in patients with congenital abnormalities is double that in normal individuals (Warburton 1991) , suggesting that there is often a causal relation between the genetic aberration and the disorder. In light of this, genes at or near translocation breakpoints are candidate disease genes, and the molecular characterisation of breakpoint regions is an obvious starting point for investigating the basis of various monogenic disorders.
This strategy has proved to be particularly fruitful in deciphering the aetiology of cognitive disorders, for which the genetic causes are extremely diverse. Due to the relative ease of identifying disease loci on the X chromosome, together with the fact that cognitive disorders are more often diagnosed in males (Chelly and Mandel 2001) , our understanding of the genetic causes for non-syndromic forms of cognitive disorders has been dominated by the identification of X-chromosomal gene defects. Many of the first of such known genes were identified through molecular characterisation of balanced translocations. Examples include TM4SF2 (Zemni et al. 2000) , ARHGEF6 (Kutsche et al. 2000) , and ZNF41 (Shoichet et al. 2003) . These results, together with the results of numerous other studies designed to identify genetic factors critical for brain development, provide the basis for our current understanding of the molecular pathways important for cognition, and certain patterns have been observed. An important insight is that many cognitive disorders can be linked to alterations in the signalling cascades associated with small GTPases, in particular those of the Rho subfamily. These proteins modulate intracellular signals, for example via signalling through the mitogen activated protein (MAP) kinase cascade, which is critical in cell differentiation, apoptosis, and regulation of the actin cytoskeleton (for review, see Kyriakis and Avruch 2001) .
The manner in which Rho-GTPase signalling is involved in the development and function of the brain is a broad field of research, and numerous genetic and functional studies contribute to the current understanding. Of the 20 known genes responsible for nonsyndromic forms of X-linked mental retardation (XLMR, reviewed in Ropers and Hamel 2005) , seven can be functionally linked to GTPase signalling, in most cases by direct association with well-characterised members of the signalling cascade. In addition, several related autosomal genes have now been linked to cognitive traits through studies on animal models or through associations with various syndromes. For example, a direct target of the XLMR-associated PAK3, LIM-kinase 1 (LIMK1), has been implicated in cognition (Frangiskakis et al. 1996) . The MEGAP/srGAP3, a GTPase activating protein expressed predominantly in brain tissue, has also been linked to cognitive deficits, through molecular characterisation of chromosome abnormalities (Endris et al. 2002) . Moreover, Wave-1, a member of a scaffolding complex important for relaying signals from the GTPases to the actin cytoskeleton, has been associated with both sensorimotor development and learning and memory in mice (Soderling et al. 2003) . Also of relevance is that the cytoplasmic FMR1-interacting protein (CYFIP1) (Schenck et al. 2001) was originally characterised by its ability to bind the active small GTPase Rac1 (Kobayashi et al. 1998) . Another example is the cyclin-dependent kinase 5, which is essential for normal brain development in mice (Ohshima et al. 1996) . It is also known for its role, together with p35, as a downstream effector of small GTPases (Nikolic et al. 1998) and as an important regulator of neuronal death and survival (for review, see Cheung and Ip 2004) . The mechanism by which alterations in signalling through Rho-GTPases result in cognitive deficits is highly complex, and it remains a subject of intense investigation.
In this study, through characterisation of the chromosome breakpoints in a patient with a balanced translocation and exhibiting a severe neurological disorder, we have linked the disorder to a truncation of the Jun N-terminal kinase 3 (JNK3) gene (also known as MAPK10), which normally functions as an effector of Rho-GTPase signalling via the MAP kinase cascade. JNK3 is best known for its role in apoptosis, but recent data point to a relevant function in neuronal differentiation and brain development (Coffey et al. 2000; Neidhart et al. 2001; Waetzig and Herdegen 2003) , which may be relevant for understanding the mechanism by which a truncated JNK3 protein could lead to the severe encephalopathy phenotype observed in the patient.
Materials and methods

Fluorescence in situ hybridisation
Patient and control samples were obtained after informed consent. Chromosome analysis was performed using standard high-resolution techniques. For breakpoint mapping, BACs, PACs and cosmid clones (the latter from a LANL chromosome 4-specific library), all available from the German Resource Center for Genome Research (RZPD), were used. Clones were prepared by standard techniques, labelled with appropriately coupled dUTPs by nick translation or directly labelled by DOP-PCR, and used as probes for fluorescence in situ hybridisation (FISH) as described previously (Wirth et al. 1999 ).
Southern blot hybridisation DNA isolation and Southern blotting was performed according to standard protocols. Probes of PCRamplified genomic DNA were labelled with 32 [P]dCTP using random hexamer primers and hybridised to membranes in PEG hybridisation buffer (10% PEG 6000, 0.125 M Na 3 PO 4 , 0.25 M NaCl, 0.001 M EDTA, 7% SDS) supplemented with salmon or herring sperm DNA. The probe used for breakpoint identification was amplified with primers 5¢-GGG TAT GCT TAT CAC CTT CAA AG-3¢ and 5¢-ATA CCA CTG GCT GCT AAG AAG G-3¢ and corresponds to nucleotides 93452-94752 of BAC RP13-514E23 (GenBank Accession Number AC104059.5).
Construction of JNK3 variants for transfection
Constructs with N-terminal JNK3 and C-terminal EGFP were created by PCR as follows: JNK3a2 was amplified with cloning primers 1 (5¢-ATT AGA TCT GTG GTA TTT ATG AGC CTC CAT TTC-3¢) and 2 (5¢-ATT GGA TCC TTT CCT GCA ACA ACC CAG GGG-3¢), digested with BglII and BamHI and cloned directionally into pEGFP-N3 (Clontech, CA, USA). The mutant was created with the same technique, using primers 1 and 3 (5¢-CTT GGA TCC GTC CCT TCC TGG AAA GAG-3¢). Construction of reciprocal constructs, with C-terminal JNK3, involved restriction endonuclease digestion of the constructs described above with the same enzymes, and cloning into pEGFP-C1 (Clontech), which harbours an N-terminal EGFP tag. For FLAG-tagged constructs, two partial JNK3 clones available from RZPD (IMAGp998G1411658Q2 and IMAGp998I2410772Q2) were used in a combination of PCR amplification reactions and restriction digests that enabled us to create a clone containing the complete coding sequence of JNK3a2, fused in frame with the FLAG motif present in the pCMVTag-2B vector (Stratagene, CA, USA). Using this clone as a template, primers 4 (5¢-ATA GGT ACC GTG GTA TTT ATG GAT TAC AAG GAT GAC-3¢) and 5 (5¢-CTA GTC TAG ATC ACC TGC AAC AAC CCA G-3¢) were used to amplify the FLAG-JNK3 wild type coding sequence, and primers 4 and 6 (5¢-ATT ACT CGA GTT AGT CCC TTC CTG G-3¢) were used to amplify the FLAG-JNK3 truncation coding sequence. Following restriction digest, both were cloned into the pcDNA3.1 vector (Invitrogen, UK) to create the expression constructs used for the immunofluorescence experiments shown.
Cell culture and transfection experiments
HeLa cells were maintained in DMEM/F12 medium with 1.5 g/l glucose and 10% foetal bovine serum, supplemented with L-glutamine and penicillin/streptomycin. Neuro2A cells were maintained in DMEM medium with 1.5 g/l glucose and 10% foetal bovine serum, supplemented with L-glutamine, non-essential amino acids, and penicillin/streptomycin. All transient transfection experiments were done with Lipofectamine 2000 (Invitrogen, CA, USA) according to the manufacturer's recommendations, except that antibiotics were removed following transfection. Lipofectamine volume was optimised with respect to DNA and cell density, and was approximately 2.5 ll/lg transfected plasmid DNA for transfection of cells at 80-90% confluency.
Immunofluorescence
At 24 or 48 h post-transfection cells were washed in PBS and fixed in 4% paraformaldehyde/PBS for 10 min. After fixation, cells were washed once in PBS and permeabilised for 10 min in 0.2% Triton-X 100/PBS. Following additional washes, cells were blocked for 30 min in blocking buffer (0.5% BSA/PBS with 0.05% Tween 20), then incubated for 1.5 h at room temperature with anti-FLAG primary antibody (1:300, Stratagene, La Jolla, CA, USA). Cells were then washed three times for 5 min in blocking buffer, and incubated for 30 min at room temperature with Cy3-conjugated secondary antibody diluted in blocking buffer (1:1,000). After further washing (three times for 5 min) in blocking buffer, cells were mounted onto slides in Vectashield Mounting Medium (Vector Laboratories, CA, USA) containing DAPI (Serva, Germany) at 1 lg/ml and visualised by fluorescence microscopy with a Zeiss Axioskop epifluorescence microscope (Carl Zeiss, Germany).
Cell fractionation and western blotting
When required, cells were stressed (UV, 312 nm) 2 h before protein extraction. Prior to harvesting, cells were washed in PBS. For whole cell extracts, cells were resuspended in lysis buffer 1 (20 mM Tris, pH 7.4; 2% SDS; 1% phosphatase inhibitor; protease inhibitor), incubated at 95°C for 5 min, briefly sonicated and centrifuged at 15,000g for 15 min. For nuclear extracts, cells were resuspended in lysis buffer 2 (10 mM HEPES, pH 7.9; 10 mM KCl; 1.5 mM MgCl 2 ; 1% phosphatase inhibitor; protease inhibitor) and incubated on ice for 10 min. After centrifugation (12,000g, 5 min), pelleted nuclei were resuspended in lysis buffer 1 and treated as described for whole cell lysates.
The microsomal fraction was obtained essentially as described previously (Gray and Whittaker 1962) . In brief, cells were resuspended in sucrose buffer (0.32 M sucrose; 4 mM HEPES, pH 7.4; 1% b-mercaptoethanol), supplemented with PMSF and Complete Protease Inhibitor Cocktail (Roche, Germany), and lysed with a Dounce homogeniser. The supernatant remaining after pelleting nuclei and cell debris (1,000g, 10 min) and cytoplasmic components including mitochondria (17,000g) was centrifuged at 1·10 5 g for 1 h resulting in the pelleted microsomal fraction. The pellet was resuspended in lysis buffer (2% Triton-X 100; 100 mM NaCl; 10 mM TrisCl, pH 8; 1 mM EDTA) supplemented with PMSF and Complete Protease Inhibitor Cocktail. Protein fractions were size separated and immunoblotted with anti-JNK antibody (1:2,000, Upstate Biotechnology, CA, USA). Following transfection experiments, nuclear and cytosolic fractions were immunoblotted with either anti-JNK antibody (1:1,000 CST, MA, USA), anti-pJNK antibody (1:2,500, Promega, Germany), or anti-pATF-2 antibody (1:1,000, CST, MA, USA) according to standard procedures.
LDH assay, statistical analysis and replication rate A commercially available lactate dehydrogenase (LDH) assay (Roche, Germany) was used according to the manufacturer's recommendations. Normal distribution of the data was verified by calculating Lilliefors probabilities based on the Kolmogorov-Smirnov test. Statistical significance was determined using the t-test for independent samples, and the respective results are displayed as means ± SD. All experiments and measurements were replicated at least three times.
Results
A male patient with a severe developmental epileptic encephalopathy carries a balanced translocation t(Y;4)(q11.2;q21)
The patient is a young male diagnosed with a pharmacoresistant epileptic encephalopathy. He was born at term after a normal pregnancy, with birth weight in the normal range (4,200 g, 90th percentile). There was no remarkable family history. His early development was also normal: he could sit at 7 months, and he walked independently and spoke a few words at 12 months. At 13 months, he presented with atonic seizures and ataxia. He remained interactive (social smile, normal fixation and pursuit). Electroencephalography (EEG) at this time showed diffuse asynchronous slow spike-wave complexes. Over the next few weeks, his interaction deteriorated, and he developed marked hypotonia and athetoid upper limb movements. He lost fine motor coordination, and he could no longer sit or walk unaided. At this time he also developed tonic seizures and partial complex seizures. Various therapies, including sodium valproate, lamotrigine, benzodiazepines, phenobarbitone, phenytoin, felbamate and carbamazepine, had little effect on the seizures. He continued to lose motor coordination skills and became progressively less interactive. From the age of two, he had several episodes of convulsive and non-convulsive status epilepticus. Steroid therapy had some effect on non-convulsive status epilepticus, but from age three, it was quasipersistent despite therapy. He received a 5-day course of oral ketamine (2 mg/kg/day), and exhibited marked improvement after 2 days. He became more alert, and seizures ceased completely for 1 week. Throughout the ketamine course, EEG showed a background of low amplitude, which was not the case before treatment. There was an excess of diffuse irregular theta activity. Discharges were rare but with very high amplitude (up to 1,300 lV). After 1 week, seizures returned, with markedly diminished intensity, and the patient remained alert. His social smile returned, he recognised his mother, and he regained some coordination. Since then, however, he has made no neurodevelopmental progress over a 6-year follow-up. Instead, seizure activity increased. Two subsequent ketamine courses resulted in positive effects, but results were not as striking as the initial response described above. The third course brought about very little change. Topiramate and levetiracetam have since been administered without significant results. Further deterioration since this time has not been observed at the clinical level, but no further testing has been done. The clinical picture is consistent with severe Lennox-Gastaut encephalopathy. Magnetic resonance imaging of the brain was normal (at the age of 7 years).
Routine karyotyping indicated the presence of a de novo balanced translocation t(Y;4)(q11.2;q21), depicted schematically in Fig. 1a . FISH mapping of genomic clones from chromosome 4q21 to patient metaphase chromosomes led to breakpoint localisation between BAC clones RP11-375K17 (GenBank accession number AC139716) and RP11-778J15 (GenBank accession number AC104827), which lie proximal and distal to the breakpoint, respectively. The Y chromosome, which presumably harbours no genes of essential importance for basic brain development, was not considered. Further studies, therefore, centred on chromosome 4q21. Screening of a chromosome 4-specific cosmid library, and subsequent FISH mapping of clones from the relevant region led to the identification of the overlapping cosmid clone LANL37D05 (Fig. 1b) . The chromosome 4 breakpoint truncates the c-Jun N-terminal kinase 3 (JNK3) gene More precise localisation of the chromosome 4 breakpoint was achieved by Southern blot hybridisation. Based on sequence from within the breakpoint-spanning cosmid clone, it was apparent that the c-Jun terminal kinase 3 JNK3 gene was affected by the translocation (Fig. 2a) . Using a probe corresponding to nucleotides 93452-94752 of clone RP13-514E23 (GenBank Accession Number AC104059.5), aberrant fragments were observed in several restriction digests (Fig. 2b) . In addition to the expected fragment sizes of 2.540 and 5.681 kb, 4.219, 2.820, 2.524, and 5.837 kb for XbaI, HincII, EcoRI, and BglII, respectively, the probe hybridises to large Y/4 hybrid fragments in each of these patient samples, indicating the proximity of the breakpoint to the probed sequence. Sequence analysis of the restriction map with respect to the JNK3 sequence indicated that the breakpoint lies within intron 9.
Expression of truncated JNK3 in a cell line from the patient JNK3 is a well-characterised serine-threonine kinase with several known isoforms, all of which harbour a well-conserved kinase domain. As described in detail by Hanks et al. (1988) , the conserved region that is responsible for the enzymatic activity of protein kinases can be divided into several domains, referred to as kinase domains I-XI; these domains were later mapped with respect to the 14 exons that make up JNK3 (Yoshida et al. 2001 ). The chromosome rearrangement in the patient results in a truncated JNK3 gene (JNK3tr), for which the predicted proteins lack the C-terminal ends, including part of the kinase domain. More precisely, the truncated JNK3a predicted protein, containing 267 amino acids, lacks kinase domains X and XI (for schematic diagram depicting the kinase domains with respect to JNK3 exons, see Fig. 3a ). As this is an autosomal gene, there is presumably one intact and functional copy of JNK3 present in the patient. As expected, wild type JNK3 could be amplified from the patient cell line by RT-PCR (data not shown). JNK3 was also investigated in the patient cell line at the protein level. Following cell fractionation of both patient and control lymphoblastoid cells and anti-JNK immunoblotting, in addition to the normal JNK isoforms with the expected sizes, a specific band at approximately 22 kD present in the microsomal fraction of the patient cell line was observed (Fig. 3b) , suggesting that at least one of the JNK3tr messages is translated in the patient instead of being subject to nonsense-mediated mRNA decay. It is therefore likely that the phenotype arises in part from a dominant effect of the truncated protein in the brain and CNS, rather than a simple partial loss of normal JNK3 function.
Aberrant cellular localisation of truncated JNK3 protein
In order to investigate the function of the JNK3tr protein, it was over-expressed in mammalian cells. Both Nand C-terminally EGFP-tagged JNK3tr proteins exhibited an aberrant localisation in both HeLa and Neuro2A cells compared to the uniform cellular distribution of the over-expressed wild type EGFP-tagged JNK3a2 control. The mutant proteins were observed in aggregates (data not shown). In order to rule out the possibility that such protein aggregates were due to misfolding caused by the large EGFP tag, N-terminally FLAG-tagged proteins were also transfected into HeLa cells and subjected to immunofluorescence with an anti-FLAG antibody. Results were similar: while the wild type protein was typically expressed uniformly, both cytoplasmic and nuclear, the mutant protein tended to form aggregates in the cytoplasm (Fig. 3c) . Observations following over-expression of JNK3tr not only suggested that this protein exhibits an aberrant localisation (Fig. 3c ), but also that relatively few cells expressed high levels of JNK3tr, suggesting cytotoxicity induced by the mutant protein. In order to investigate this observation more quantitatively, over-expressed proteins were assessed by western blotting (Fig. 4) .
As expected, we could not detect any phosphorylated JNK3tr-EGFP in nuclear extracts using a phosphospecific anti-JNK antibody, whereas phosphorylated (active) wild-type JNK3-EGFP was clearly present (Fig. 4a) . Still, stress-induced activation of JNKs, as assayed by phosphorylation of the transcription factor ATF2, must be due to endogenous JNKs in the cells expressing the truncated isoform (Fig. 4a) . Moreover, analysis of over-expressed non-phosphorylated (inactive) tagged proteins in both nuclear and cytoplasmic extracts indicated a great difference in expression levels of wild-type and truncated proteins. Even in cytoplasmic extracts, only the wild-type form could be detected (Fig. 4b) . These results support the hypothesis that the cells respond negatively to high levels of JNK3tr, and that it is targeted for degradation. This idea was confirmed by experiments in which protein degradation was blocked using the proteasome inhibitor MG132. In the presence of this inhibitor, the over-expressed JNK3tr protein, together with the normal isoforms, could be detected using an anti-JNK antibody (Fig. 4c) , confirming that proteasome-mediated degradation of the over-expressed truncated protein indeed occurs. Even under these conditions, however, only the inactive nonphosphorylated form of the over-expressed JNK3tr could be detected, which rules out the possibility that the protein plays even a restricted role as a classical kinase.
In order to investigate the condition of the cells overexpressing the truncated protein, cytotoxicity, based on LDH levels in the cell culture medium, was measured (Fig. 4d ). There were no observable differences between LDH levels of wild-type and truncated JNK3-expressing cells 24 h post-transfection. However, at 48 h posttransfection, samples in which the proteasome had been blocked, i.e. those expressing significant levels of JNK3tr, exhibited increased levels of LDH with respect to both vector-transfected and wild-type JNK3-expressing cells. The observed difference was highly significant in experiments with the inhibitor MG132. Together, these data confirm that JNK3tr indeed has a detrimental effect on its cellular environment. Given that the JNK3 protein is normally expressed specifically in the CNS, this result supports the idea that the patient phenotype is at least in part due to dominant effects of the mutant protein in the affected cells. It is plausible that the truncated JNK3 causes neurological damage before degradation can be completed.
Discussion
There are now more than 60 known single gene defects responsible for syndromic and non-syndromic forms of XLMR (Ropers and Hamel 2005) , and recently, several autosomal genes for mental retardation have also been identified. Combined, these studies indicate that a diverse set of molecular cascades are critical for normal cognitive function. The specific pathway with perhaps the longest historical association with cognition is that mediated by the Rho family of small GTPases (Chelly and Mandel 2001; Ramakers 2000 Ramakers , 2002 . This subfamily has been distinctively linked to the JNK branch of the MAP kinase cascade in several independent studies (Coso et al. 1995; Minden et al. 1995; Yamauchi et al. 2001) , which has particular relevance given our results. The JNK3 gene is a novel candidate disease gene for a seizure-associated mental disorder. We have shown that it is disrupted by a balanced translocation in a patient with severe motor and cognitive delay and seizures, a clinical picture typical for Lennox-Gastaut encephalopathy. Given the timing of the onset of the disorder (13 months, which was also the point at which the seizures were first observed), it is important to acknowledge that the motor and cognitive delay in the patient could be a secondary result of the observed seizures. However, as we discuss here, given the disruption of the JNK3 gene, which is an obvious candidate gene for mental deficits based on its role in cascades that have been implicated in various forms of non-syndromic mental retardation, we consider a mechanistic model in which both the seizure disorder and the mental retardation arise from defects in the CNS-expressed JNK3 protein.
JNK proteins are a subset of MAP kinase signalling molecules well-known for their role in the apoptotic process in the nervous system (Brecht et al. 2005; Kuan et al. 1999; Yang et al. 1997 ), but also recognised for their role in neuronal differentiation (Coffey et al. 2000; Waetzig and Herdegen 2003) . There are three known JNK proteins (JNKs 1, 2 and 3) with a total of ten isoforms, all of which are expressed in the CNS. JNK3 is the only member of this subfamily with predominant expression in the brain; it is logical, therefore, to expect that this gene has specific importance for neuronal development and function. Moreover, both the heterozygous and homozygous Jnk3 knockout mice exhibit abnormal responses to seizure induction (Brecht et al. 2005; Yang et al. 1997) , which provides an additional link to the patient investigated, given his severe seizure disorder.
JNK3 is disrupted by the patient's chromosome 4 breakpoint, resulting in a truncated JNK3 protein that is detectable in the patient cell line. Over-expression studies demonstrated that the truncated protein behaves unlike the wild-type protein in mammalian cells, and that cells respond negatively in its presence. Taken together with the established role of JNK3 in neurons, our data suggest that the chromosome aberration causes the patient phenotype, but the precise mechanism remains unknown.
The mutant protein retains residues 221-223 (TPY), which, in the normal JNK3, is the site of phosphorylation by upstream MAP kinase kinases MKK4 and 7 (Ip and Davis 1998) . Although the kinase domain is interrupted, which most likely abolishes its catalytic activity, approximately 60% of the protein remains intact. It is likely that such a truncated JNK3 will exhibit modified protein-protein interactions, which might also be caused by misfolding. Altered localisation and degradation of the mutant protein, perhaps together with specific binding partners, would influence normal signalling through JNK3 and potentially affect related pathways in which JNK3 binding plays a role. The phenotype therefore likely results from a combination of JNK3 haploinsufficiency and dominant effects of the truncated protein, which probably include both cytotoxic effects and altered protein-protein interactions.
JNKs make up one of several distal branches of the Rho-GTPase-mediated signal transduction network. This link was first reported in studies in which activation of Rac1 and Cdc42, but not RhoA, led to up-regulation of the JNK signalling pathway (Minden et al. 1995) . There is general agreement that activation of the Rho-GTPases Rac1 and Cdc42 tends to promote neurite outgrowth, whereas activation of RhoA-dependent cascades tend to have inhibitory effects (Luo 2000; Nikolic 2002 ). Interestingly, recent studies have also directly implicated the JNKs in neuronal differentiation and neurite outgrowth. For example, over-expression of JNK3 enhances neurite outgrowth in PC12 cells (Waetzig and Herdegen 2003) , which supports the model in which Rac1/Cdc42-mediated positive regulation of neurite outgrowth is JNKdependent. This model is especially attractive in the light of our results. A non-functional JNK protein such as the truncated JNK3 present in the patient could, for example, sequester JNK binding partners involved in this cascade, thereby preventing normal JNK activation and inhibiting neurite outgrowth.
Perhaps of greatest significance, however, are studies that directly implicate proteins in JNK3 binding. JNK interacting protein 3 (JIP3, also known as JNK/stress activated protein kinase-associated protein 1, or JSAP1), known for its role as a JNK scaffold, exhibits predominant expression in the brain, and has particular affinity for binding to JNK3, in comparison with JNKs 1 and 2 (Ito et al. 1999; Kelkar et al. 2000) . It is also phosphorylated by JNK3 (Ito et al. 1999) . Another JNK scaffold, b-arrestin 2, is of relevance for similar reasons. It interacts with both JNK3 and its upstream regulators, and facilitates JNK3 phosphorylation (McDonald et al. 2000; Miller et al. 2001) . Moreover, b-arrestin 2-mediated JNK activation is specific for JNK3 (McDonald et al. 2000) . It is reasonable to suspect that JNK3 may have a specific role in the CNS together with any or several of these brain-expressed scaffolding proteins, and that this role may be independent of the apoptosis-related roles of JNKs in multiple cell types. Further evidence in support of this theory is provided by our study in which JNK3 over-expression clearly promoted neurite outgrowth (Waetzig and Herdegen 2003) .
Given the role of JNK activation in GTPase-mediated cascades, and the established function of JNK3 in regulation of neurite outgrowth and neuronal apoptosis, partial loss of function of JNK3 could lead to neuronal malformations that result in seizures, mental retardation and neurodegeneration. However, studies on both heterozygous and homozygous Jnk3 knockout mice, which show no obvious developmental phenotype, do not support a model based exclusively on haploinsufficiency. Mice with reduced or absent Jnk3 protein are resistant to induced seizures, but pathological studies on the brains of these mice showed no morphological changes indicative of defective neuritogenesis (Yang et al. 1997) . These data support the known role of JNK3 as a stress-activated mediator of apoptotic cascades, and suggest that aberrant JNK3 function may play a role in the seizures in our patient. The absence of observed defects in neurite outgrowth is in line with our hypothesis that the truncated JNK3 in our patient, which maintains approximately 60% of the residues present in the wild-type isoforms, may play a dominant role by disrupting normal signalling cascades critical for neurite outgrowth and differentiation.
Very likely, the patient's phenotype results at least in part from a dominant effect of the truncated protein on the normal JNK3 interactions we have outlined. Together with a simultaneous partial loss of any JNKdependent stimulatory effects on neurite outgrowth, it is easy to see that such alterations could have detrimental effects on neural development. 
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